Search clinical trials for: BCA101

Total 185 results

He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
Biophytis

Terminated

Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients (COVA)

Covid-19 | SARS-CoV2

United States, Belgium, France, Brazil, Puerto Rico
Medtronic BRC

Terminated

Impedance Measurements in Heart Failure Patients (SIM-HF)

Heart Failure

Czech Republic, Germany, Slovakia
SCG Cell Therapy Pte. Ltd.

Recruiting

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma (TCR-T)

Hepatocellular Carcinoma Recurrent | Hepatitis B Virus Related Hepatocellular Carcinoma

United States, Singapore, Hong Kong
MetaFines

Completed

Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors

Solid Tumor

Korea, Republic of, United States
Bionovo

Completed

A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer

Metastatic Breast Cancer
Bionovo

Unknown

A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Hugel

Completed

Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers

Hypertrophic Scar

Korea, Republic of
Hugel

Terminated

the Hypertrophic Scar Prevention of BMT101.

Hypertrophic Scar

Korea, Republic of
The First Affiliated Hospital with Nanjing Medical...
Nanjing Bioheng Biotech Co., Ltd.

Unknown

CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Kai Lin Xu; Jun Nian Zheng
Nanjing Bioheng Biotech Co., Ltd.

Unknown

CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
Transonic Systems Inc.
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Cardiac Output Measurement at the Conclusion of Cardiopulmonary Bypass

Cardiac Output

United States
CHABiotech CO., Ltd

Completed

Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer

Solid Tumor

Korea, Republic of
Peking Union Medical College Hospital
Stanford University

Unknown

68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

China
Bionomics Limited
CPR Pharma Services Pty Ltd, Australia

Terminated

A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.

Colorectal Cancer

Australia
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Recruiting

A Phase I Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
GeneCradle Inc

Recruiting

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients

SMA II

China
Can-Fite BioPharma

Completed

Safety and Efficacy Study of CF101 to Treat Psoriasis

Plaque Psoriasis

Israel
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects

Pharmacokinetic Study

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Advanced Malignant Tumor

China
Ivix LLX

Completed

BP101 for Adults With Female Sexual Dysfunction

Female Sexual Dysfunction | Hypoactive Sexual Desire Disorder | Sexual Desire Disorder

Russian Federation
Peking Union Medical College Hospital

Recruiting

Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC

Hepatocellular Carcinoma

China
JW Pharmaceutical

Completed

To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension

Hypertension | Dyslipidemia

Korea, Republic of
Bicara Therapeutics
Merck Sharp & Dohme LLC

Recruiting

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Head and Neck Neoplasms | Carcinoma, Squamous Cell | Colorectal Cancer | Squamous Cell Carcinoma of Head and Neck | Epithelial Ovarian Cancer | Head and Neck Squamous Cell Carcinoma | Pancreas Cancer | Squamous Cell Carcinoma of the Lung | Cutaneous Squamous Cell Carcinoma | Squamous Cell Carcinoma of... and other conditions

United States, Canada
Can-Fite BioPharma
Rabin Medical Center

Completed

Piclidenoson for Treatment of COVID-19

COVID-19 | Coronavirus Infection

Israel, Bulgaria, Romania
Finch Research and Development LLC.

Withdrawn

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT) (SPROUT)

Autism Spectrum Disorder | Autism | ASD | FMT | Fecal Transplant | Autistic Thinking | Autistic Behavior | Fecal Microbiota Transplant | Finch | CP101 | SPROUT
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)

Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)

China
GeneCradle Inc

Recruiting

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients

Spinal Muscular Atrophy

China
Ivix LLX

Completed

Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire

Hypoactive Sexual Desire Disorder (HSDD)

Russian Federation
Patara Pharma

Completed

Treatment of Refractory Chronic Cough With PA101

Refractory Chronic Cough

Netherlands, United Kingdom
Technische Universität Dresden
German Cancer Research Center

Recruiting

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (CARLOTTA01)

Neoplasms | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Germany
Octapharma

Terminated

Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria
Finch Research and Development LLC.

Terminated

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) (PRISM4)

Recurrent C. Difficile Infection

United States, Canada
Ivix LLX

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers

Hypoactive Sexual Desire Disorder(HSDD)

Russian Federation
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics

Advanced Cancer

China
Can-Fite BioPharma

Completed

Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca

Keratoconjunctivitis Sicca

Israel
BioGenCell Ltd.
Rabin Medical Center; Laniado Hospital

Recruiting

BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI) (EnEPC-CLI)

Peripheral Arterial Disease | Peripheral Vascular Disease | Critical Limb Ischemia

United States, Israel
Can-Fite BioPharma

Completed

Trial of CF101 to Treat Patients With Dry Eye Disease

Keratoconjunctivitis Sicca

Israel
Xoc Pharmaceuticals

Active, not recruiting

Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects

Migraine

United States
FBD Biologics Limited

Recruiting

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Advanced Solid Tumor | Refractory Non-Hodgkin Lymphoma

Taiwan, United States
Nohla Therapeutics, Inc.

Terminated

NLA101 in Adults Receiving High Dose Chemotherapy for AML (LAUNCH)

Leukemia, Myeloid, Acute

United States, Korea, Republic of, Australia
Can-Fite BioPharma

Completed

Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure

Ocular Hypertension | Glaucoma

Israel, Bulgaria
Shanghai General Hospital, Shanghai Jiao Tong University...
RenJi Hospital

Not yet recruiting

Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients With Advanced Solid Tumors

Solid Tumor

China
Shanghai Juncell Therapeutics

Recruiting

A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002) (MIZAR-002)

Melanoma | Efficacy | Adverse Drug Event | Safety | Tumor Infiltrating Lymphocytes

China
Can-Fite BioPharma

Completed

Trial of CF101 to Treat Patients With Psoriasis

Plaque Psoriasis

Israel, United States, Bulgaria, Romania
Can-Fite BioPharma

Withdrawn

Safety &Efficacy of CF101 to Subjects With Uveitis

Uveitis, Posterior | Uveitis, Intermediate

Israel
Can-Fite BioPharma

Terminated

CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis

Rheumatoid Arthritis

Bosnia and Herzegovina, Canada, Israel, Moldova, Republic of, Poland, Romania, Serbia
Can-Fite BioPharma

Withdrawn

A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee

Osteoarthritis of the Knee

Israel
Biophytis

Completed

A Double-blind, Placebo Controlled, Randomized INTerventional Clinical Trial (SARA-INT) (SARA-INT)

Muscle Weakness | Sarcopenia | Gait Disorders in Old Age

United States, Belgium

Search clinical trials for: BCA101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations